Risk of end-stage renal disease associated with gout: a nationwide population study by unknown
RESEARCH ARTICLE Open Access
Risk of end-stage renal disease associated with
gout: a nationwide population study
Kuang-Hui Yu1,2, Chang-Fu Kuo1,3*, Shue-Fen Luo1,2, Lai-Chu See4,5, I-Jun Chou6, Hsiao-Chun Chang1 and
Meng-Jiun Chiou4,5
Abstract
Introduction: We explored the risk of end-stage renal disease (ESRD) among gout patients in a representative
cohort in Taiwan.
Methods: The primary database used was the Taiwan National Health Insurance Research Database. Subjects older
than 20 years without ESRD, coronary heart disease, or stroke were included in the study. The case definition of
gout in the present study was gout diagnosis and medical treatment for gout. An ESRD case was defined by the
presence of chronic renal failure necessitating long-term renal replacement therapy. Multivariate Cox proportional
hazards models were used to evaluate the risk of ESRD among gout patients.
Results: The analysis included data of 656,108 patients who were followed up for a mean of 8.0 years. Among
them, 19,963 (3.0%) patients had gout. At the end of 2008, 2,377 individuals (gout, n = 276; non-gout, n = 2,101)
had ESRD, and 861 individuals (gout, n = 77, 27.9%; non-gout, n = 521, 24.8%) died due to ESRD. The rates of
incidence of ESRD were 1.73 and 0.41 cases per 1,000 patient-years in the gout and non-gout groups. After
adjustment for age, sex, and history of diabetes mellitus and/or hypertension, gout was associated with a hazard
ratio (HR) of 1.57 for ESRD (95% confidence interval [CI], 1.38-1.79; P < 0.001). In patients with ESRD, the adjusted
HR for death in patients with gout was 0.95 (0.74-1.23, P = 0.71), which was similar to the HR obtained in patients
without gout.
Conclusions: Gout is associated with an increased hazard for development of ESRD.
Introduction
Chronic kidney disease (CKD) is the progressive loss of
renal function over a period of months or years. Contin-
uous deterioration of renal function in patients with
CKD eventually leads to the development of end-stage
renal disease (ESRD). Patients with ESRD require renal
replacement therapy, such as hemodialysis, peritoneal
dialysis, or kidney transplantation, for sustenance. ESRD
is increasingly becoming a major health burden world-
wide [1,2]. The prevalence and incidence of ESRD are
alarmingly high in Taiwan in particular [3]. A recent
study based on data from the National Dialysis Registry
of Taiwan revealed that 48,072 patients required hemo-
dialysis and 4,465 required peritoneal dialysis in 2007;
these numbers correspond to a prevalence of 2,288
ESRD cases per population of 1,000,000 [4].
Traditionally, diabetes mellitus (DM) and hypertension
have been considered the most important risk factors
for CKD [5-7]. Since gout frequently coexists with DM
[8] and hypertension [9], it is often overlooked as a gen-
uine risk factor for CKD and subsequent ESRD [10].
Studies in humans have provided limited evidence of
the link between hyperuricemia, which is the biochem-
ical hallmark of gout, and deterioration of renal function
[11]. A previous study reported the existence of a mod-
est but significant association between the quintiles of
uric acid levels and deterioration of renal function [12].
Another study found that the risk for CKD increased
1.69-fold for every 2-mg/dL increase in uric acid levels
[13]. Our recent study revealed that hyperuricemia was
strongly associated with CKD independently of the pre-
sence or absence of the metabolic syndrome [14]. More-
over, subjects with hyperuricemia are more likely to
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develop ESRD than are those without hyperuricemia
[15]. However, the role of gout as an independent risk
factor of CKD/ESRD has not yet been explored. By ana-
lyzing the data obtained for a representative cohort of
the general population in Taiwan, the present study
sought to determine whether gout independently
increased the hazard of development of ESRD.
Materials and methods
This study was approved by the institutional review
board of the Chang Gung Memorial Hospital in Taiwan
(approval number 97-1564C) and was conducted in full
compliance with the local and national ethical and regu-
latory guidelines. The primary data sources of this pro-
spective observational study were the Taiwan National
Health Insurance Research Database (NHIRD) and the
National Death Registry in Taiwan. This study was sup-
ported by a research grant from the Chang Gung Mem-
orial Hospital. The study was designed and the data
collected, analyzed, and interpreted by the investigators
independently.
Study population
The Taiwan National Health Insurance (NHI) system
was established in 1995 and requires all residents of Tai-
wan to participate. At the end of 2010, 23.03 million
residents of Taiwan were enrolled in this system. The
NHI database contains the registration files and original
claims data, including comprehensive information on
demographics, inpatient and ambulatory care, diagnostic
codes, medical expenditure, operations, prescriptions,
examinations, and procedures.
The Taiwan NHIRD releases sets of sampling files,
called the Longitudinal Health Insurance Database
(LHID), for research purposes. LHID 2000 contains the
entire original claims data for 1,000,000 beneficiaries
randomly sampled from the entire population of NHI
beneficiaries in the year 2000. The source population
was the entire population covered by NHI (23,753,407
individuals) in the year 2000. The sampling procedure
was detailed on the website of National Health Research
Institute [16] and is summarized briefly in the following
text. Each individual was assigned a serial number ran-
ging from 1 to 23,753,407. By means of a linear con-
gruential random number generation method, 1,000,000
non-duplicated random numbers were generated. Indivi-
duals with serial numbers corresponding to these num-
bers were selected. All registration and claims data for
these 1,000,000 individuals, recoded for the period of
1996 to 2008, were collected and distributed as LHID
2000. The subjects included in LHID and those enrolled
in the original Taiwan NHIRD do not differ significantly
in terms of age, sex, or mean insured amount.
Any insured citizen with a major disease can apply for
a catastrophic illness certificate, which entitles the
holders to subsidies and waivers of the outpatient and
inpatient copayments. The prerequisites for the issuance
of this certificate are a diagnosis of catastrophic illness
by a physician and a formal review by the Bureau of
National Health Insurance. ESRD is also listed as a cata-
strophic illness.
In this study, we used LHID 2000 as the primary
source of data. The eligible criteria included (a) age at
least 20 years and (b) the absence of ESRD, coronary
heart disease (CAD), and stroke before the year 2000.
Subjects were classified by a history of gout before 1
January 2000.
Case definition of gout
The case definition of gout in the present study con-
sisted of a gout diagnosis (International Classification of
Diseases, Ninth Revision [ICD-9] code 274.x) and medi-
cal treatment for gout at either an outpatient or emer-
gency department during 1996 to 1999. The definition
of medical treatment consisted of the use of colchicine
and the use of urate-lowering agents (including benz-
bromarone, allopurinol, probenecid, and sulfinpyrazone).
We also used a secondary case definition (clinical diag-
nosis with gout in records of two visits to outpatient or
emergency departments) for gout in this study. As the
results were similar and did not change the overall con-
clusion, we reported results using the primary case defi-
nition. The utility and validity of gout diagnoses in
claims data had been assessed. Positive predictive values
of gout diagnosis recorded in the database had been
reported to range from 61% [17] to 100% [18].
Definition of outcome
The primary outcome was ESRD. Patients with ESRD
require chronic renal replacement therapy, including
hemodialysis, peritoneal dialysis, and kidney transplanta-
tion, to survive, and this fulfills the requirement for a
catastrophic illness certificate in Taiwan. Thus, we iden-
tified patients with ESRD by linking the LHID to the
registry for catastrophic illnesses.
Definition of baseline risk factors
All of the outpatient records were screened for patients
who required treatment for DM (ICD-9 code 250) and
hypertension (ICD code 401-405) on two or more
occasions.
Survival status
The survival status and cause of death in the event of
fatality of the subjects between 2000 and 2008 were
ascertained by using the National Death Registry in
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Taiwan, which records the cause of death for all
deceased citizens.
Statistical analysis
Subjects were followed up from 1 January 2000 to the
date of issuance of ESRD certificates or death or the
end of the study (31 December 2008), whichever was
earliest. The ESRD incidence was calculated as the ratio
of the number of incident ESRD cases to the population
count in LHID 2000 and was expressed as the annual
incidence per population of 1,000.
The difference in the incidence of ESRD among
patients with gout and those without gout was analyzed
by using the log-rank test. Cox proportional hazards
models were constructed with the dichotomous variable
denoting whether the patient had ESRD during the
study period. Covariates used in the models included
age, sex, and history of DM or hypertension between
1996 and 1999. Hazard ratios (HRs) and 95% confidence
intervals (CIs) were computed. A two-sided P value of
less than 0.05 was considered statistically significant. All
analyses were performed by using PASW Statistics, ver-
sion 18, and PASW Modeler, version 13 (SPSS Inc., Chi-
cago, IL, USA).
Results
After exclusion of subjects with a history of ESRD,
CAD, or stroke, we selected 656,108 subjects (336,733
men and 319,375 women) who were at least 20 years
old. Gout was diagnosed in 19,963 (3.0%) of the patients
between 1996 and 1999; 14,542 (72.8%) were male. The
mean age of the patients was 41.1 ± 15.6 years, and
there was no difference between the sexes. However,
patients with gout were significantly older than the
others (52.2 ± 15.2 versus 40.7 ± 15.4 years).
Table 1 summarizes and compares the baseline char-
acteristics between patients with gout and those without
gout. In general, patients with gout were significantly
more likely to develop DM and hypertension, and odds
ratios (ORs) were 5.94 and 7.21, respectively.
The cohort was followed for a total of 5,242,530 per-
son-years from January 2000 for a mean follow-up per-
iod of 8.0 ± 0.2 years. During the study period, ESRD
was diagnosed in 2,377 patients (276 with gout and
2,101 without gout) and chronic renal replacement ther-
apy was required. The incidences of ESRD among
patients with gout and those without gout were 1.73
and 0.41 per 1,000 person-years (log-rank test, P <
0.001), respectively. The incidence of ESRD did not dif-
fer between the sexes.
Next, we conducted multivariate Cox proportional
models to determine the adjusted HR for ESRD in gout.
Gout was associated with an age- and sex-adjusted HR
(95% CI) of 1.75 (1.59 to 1.94) for ESRD. After adjust-
ment for age, sex, and history of DM and } hyperten-
sion, gout was associated with an HR of 1.57 (95% CI
1.38 to 1.79; P < 0.001) for ESRD (Table 2).
In patients with ESRD, 861 individuals - 77 with gout
(27.9%) and 521 without gout (24.8%) - died due to
ESRD. The presence of gout did not increase the risk of
death to a level greater than that in those without gout.
The log-rank test showed no survival difference between
ESRD patients with gout and those without gout (P =
0.21). After adjustment for age, sex, and history of DM
and hypertension, gout was associated with an adjusted
HR of 0.95 (95% CI 0.74 to 1.26; P = 0.71) for mortality.
Among patients without DM and hypertension (n =
599,450), a higher risk of ESRD was also observed in
patients with gout than in those without gout. During
4,792,542 person-years of follow-up, 1,132 subjects
developed ESRD (70 with gout and 1,062 without gout),
corresponding to rates of incidence of ESRD of 0.70 and
0.22 per 1,000 person-years (log-rank test; P < 0.001) for
patients with gout and those without gout, respectively.
Among subjects without DM and hypertension, gout
was associated with an age- and sex-adjusted HR of 2.00
(95% CI 1.56 to 2.56; P < 0.001) for ESRD.
Next, we explored the association between gout and
ESRD in three age groups (20 to 44 years, 45 to 59
years, and at least 60 years). Risk for ESRD in patients







Age in years, mean ± SD 52.2 ± 15.72 40.7 ± 15.4
Males, number (percentage) 14,542 (72.8%) 322,191 (50.6%)
Years of follow-up, mean ± SD 8.0 ± 0.4 8.0 ± 0.2
DM, number (percentage) 2,619 (13.1%) 18,507 (2.9%) 5.94 (4.82-5.26)
Hypertension, number (percentage) 6,311 (31.6%) 38,336 (6.0%) 7.21 (7.00-7.44)
DM or hypertension, number (percentage) 7,367 (37.4%) 49,190 (7.7%) 7.13 (6.92-7.35)
DM and hypertension, number (percentage) 1,463 (7.3%) 7,653 (1.2%) 6.49 (6.13-6.88)
CI, confidence interval; DM, diabetes mellitus; SD, standard deviation.
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with gout was higher among older subjects. For those
who were 20 to 44 years old, gout was not indepen-
dently associated with ESRD after adjustment for age,
sex, DM, and hypertension. However, gout was asso-
ciated with HRs of 1.41 and 1.58 for ESRD in patients
who were 45 to 59 years old and those at least 60 years
old, respectively (Table 3).
Discussion
Investigation of data recorded for a representative
cohort of the general population in Taiwan revealed
that gout was independently associated with an HR of
1.57 for ESRD after adjustment for age, sex, and history
of DM and hypertension. Among subjects without a his-
tory of DM or hypertension, the risk for ESRD in
patients with gout was twofold that in those without
gout. The risk of ESRD was not significantly high for
younger patients (20 to 44 years old) but increased with
age after 45 years. Mortality among patients with ESRD
was not affected by the presence or absence of gout.
Since patients with gout were 57% more likely to
develop ESRD, the specific risk for death due to ESRD
remained higher in the gout-affected population than in
the normal population. This result was consistent with
our recent finding that gout was associated with a three-
fold standardized mortality ratio for kidney disease [19].
Overall, gout is associated with a greater hazard of
development of ESRD.
CKD is an important public health problem. The
direct and indirect costs of caring for patients with CKD
are enormous, particularly for those requiring chronic
renal replacement therapy [20]. Fortunately, early
detection and prompt treatment of CKD may prevent or
delay its complications [21]. However, because it is fre-
quently asymptomatic, early-stage CKD is often over-
looked [22]. Proteinuria [23], hypertension [24],
hyperglycemia [25], and metabolic syndrome [26] are
well-documented risk factors for CKD and are fairly
common in patients with gout. Consistent with these
findings, this study showed that gout was associated
with a sixfold risk for DM and a sevenfold risk for
hypertension. Our previous study also revealed higher
percentages of proteinuria in patients with gout (9.8%)
than in subjects with hyperuricemia (7.8%) or normouri-
cemia (4.4%) [27]. Since the clinical presentation of gout
is more prominent than that of the other risk factors of
CKD, a diagnosis of gout should be regarded as a warn-
ing sign for CKD and a thorough assessment of kidney
function is warranted.
Among patients with ESRD, the mortality of patients
with gout was similar to that of patients without gout.
This finding seems to be contrary to that of a previous
study, which reported that gout was associated with an
adjusted HR of 1.49 for mortality [28]. However, the
case definition for gout in that study was different: we
evaluated gout patients before they developed ESRD,
whereas Cohen and colleagues [28] evaluated patients
both developing gout and undergoing dialysis treatment.
Gout incidence was thought to be low among patients
with ESRD [29], probably because inflammatory media-
tors are removed by dialysis [30]. Incident gout after
initiation of dialysis may represent a higher metabolic
disturbance or level of inflammation among patients
with ESRD and therefore leads to an increased risk of
death. Further investigation is required to confirm this.
The reason for the increased risk of ESRD among peo-
ple with gout is unclear. Hyperuricemia has been linked
to reduced renal function and the development and pro-
gression of renal disease. In a previous study, hyperuri-
cemia was found to be associated with an adjusted OR
of 1.82 for the deterioration of kidney function [31].
Another study indicated that, for every 2-mg/dL
increase in serum uric acid level, the OR for new-onset
kidney disease was 1.69 [13]. A uric acid level of 7.0 to
8.9 mg/dL was reported to be associated with an OR of
1.74 for incident kidney disease after adjustment for
baseline glomerular filtration rate [32]. A recent trial
randomly assigned 54 patients with CKD to allopurinol
treatment or control groups and demonstrated that a
reduction in serum uric acid levels mitigated the pro-
gression of CKD [33]. Besides coexisting with hyperuri-
cemia, gout often coexists with hypertension and DM,
as was the case in the present study. Moreover, patients
with gout are more likely to have received non-steroid
anti-inflammatory drugs, which have been documented
to be a risk factor for ESRD [34].
Table 2 The association between gout and the
occurrence of end-stage renal disease
Covariates HR (95% CI) P value
Gout 1.57 (1.38-1.79) < 0.001
Age 1.027 (1.02-1.03) < 0.001
Male gender 1.04 (0.96-1.12) 0.395
Diabetes mellitus 6.20 (5.61-6.85) < 0.001
Hypertension 2.18 (1.97-2.42) < 0.001
CI, confidence interval; HR, hazard ratio.
Table 3 Risk for end-stage renal disease among patients












5,832 (1.4%) 3,989 (3.5%) 2,675 (4.1%)
ESRD, gout/non-gout 16/397 26/364 28/301





CI, confidence interval; ESRD, end-stage renal disease; HR, hazard ratio.
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Use of administrative databases enables population-
based epidemiologic studies; however, limitations exist.
The inability to apply clinical case definitions, particu-
larly in a common complex disease such as gout, is
one of the inherent limitations. Currently, there are
three classification criteria for gout [35-37]. In many
cases (in particular, in studies based on administration
databases), none of the aforementioned criteria can be
applied, because of the lack of clinical detail and
laboratory parameters, regardless of how good the dif-
ferential power of the previous classification criteria
may be. In such settings, the identification of gout
cases often depends on patient recall or physician diag-
nosis. For self-report physician diagnosis of gout, a
recent study suggests that it has good reliability and
sensitivity [38]. The utility and validity of gout diag-
noses in claims data had also been assessed [17,18].
Harrold and colleagues [17] demonstrated that gout
diagnosis on two or more occasions portended a posi-
tive predictive value of 61%. In another study, Jasvin-
der and colleagues [18] found that ICD-9 codes for
gout had a sensitivity of 90%, a specificity of 100%, and
positive and negative predictive values of 100% and
87%, respectively. Recently, Mikuls and colleagues [39]
used a case definition based on the use of anti-gout
treatment. Using both diagnosis and treatment to
define a patient with gout should result in a case defi-
nition that is more stringent than one that defines
cases on the basis of diagnoses only. The decision of
case definition in epidemiological studies should be
made on an individual basis. In this study, two case
definitions were used, and they produced similar
results. This reinforces our conclusion that patients
with gout have a higher risk of ESRD.
Other limitations of this study merit discussion. First,
we had no information on some potential covariates,
such as serum uric acid or creatinine levels. Socioeco-
nomic status has been mentioned as a risk factor for
ESRD [40]; however, there was no proper surrogate
marker to represent socioeconomic status in the data-
base. Therefore, these factors could not be included in
the modeling process. Second, the use of administra-
tive claims data also precluded adjustment for lifestyle
covariates, such as diet and smoking. Despite these
limitations, the results can be generalized and are
applicable to the general population because the study
is population-based. Furthermore, since the primary
data source was claims data of the Taiwan NHIRD,
which covers almost the entire population in Taiwan,
and the information regarding exposure, outcome, and
covariates was prospectively collected, the possibility of
missing data or loss to follow-up is almost non-
existent.
Conclusions
The present study demonstrated that gout indepen-
dently increased the hazard of development of ESRD,
and the magnitude of hazard in the gout-affected popu-
lation was 57% higher than that in the general popula-
tion. The risk was significant even among patients who
had gout but not DM or hypertension. These findings
justify the careful monitoring of renal function in
patients with gout.
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